High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab – a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)

Vedolizumab as Induction and Maintenance Therapy for Crohnʼs Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy

(2017) Bruce E. Sands et al.   INFLAMMATORY BOWEL DISEASES

OP020 Recent anti-TNF exposure predicts lower vedolizumab trough concentrations in patients with Crohn's disease

(2017) A. Gils et al.   Journal of Crohns & Colitis

Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn’s Disease and Ulcerative Colitis

(2017) Maja Noman et al.   Journal of Crohns & Colitis

Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)

(2017) Carl Eriksson et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study

(2016) A. Stallmach et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium

(2016) Parambir S Dulai et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Real-World Evidence — What Is It and What Can It Tell Us?

(2016) Rachel E. Sherman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loss of Response to Anti-TNFs: Definition, Epidemiology and Management

(2016) Giulia Roda et al.   Clinical and Translational Gastroenterology

Risk of infections associated with biological treatment in inflammatory bowel disease

(2016) Nynne Nyboe Andersen et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Systematic Information to Health-Care Professionals about Vaccination Guidelines Improves Adherence in Patients With Inflammatory Bowel Disease in Anti-TNFα Therapy

(2015) Katrine R Christensen et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice

(2015) Emily E. Vivio et al.   Journal of Crohns & Colitis

Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

(2014) Bruce E. Sands et al.   GASTROENTEROLOGY

The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease

(2014) Kaija-Leena Kolho et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Vedolizumab for the Treatment of IBD: A Selective Therapeutic Approach Targeting Pathogenic a4b7 Cells

(2013) Manol Jovani et al.   CURRENT DRUG TARGETS

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

(2012) Geert DʼHaens et al.   INFLAMMATORY BOWEL DISEASES

Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD

(2012) Pauliina Molander et al.   Journal of Crohns & Colitis

Incidence and US Costs of Corticosteroid-Associated Adverse Events: A Systematic Literature Review

(2011) Evelyn Sarnes et al.   CLINICAL THERAPEUTICS

Inflammatory Bowel Disease

(2009) Clara Abraham et al.   NEW ENGLAND JOURNAL OF MEDICINE

The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use

(2009) Stephanie C. Manson et al.   RESPIRATORY MEDICINE

Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment

(2009) Taina Sipponen et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY